Efficacy and safety of nusinersen in children with later-onset spinal muscular atrophy (SMA): interim results of the phase 3 CHERISH study

被引：0
|
作者：
Finkel, Richard
Mercuri, Eugenio
Kirschner, Jan
Chiriboga, Claudia A.
Kuntz, Nancy
Darras, Basil T.
Shieh, Perry B.
Saito, Kayoko
De Vivo, Darryl
Day, John W.
Mazzone, Elena S.
Montes, Jacqueline
Yang, Qingqing
Zhong, Zhenshao John
Gheuens, Sarah
Bennett, C. Frank
Schneider, Eugene
Farwell, Wildon
机构：
来源：
NEUROLOGY | 2017年 / 89卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：E100 / E101
页数：2
相关论文
共 50 条
  • [21] Relationship of pharmacokinetics and pharmacodynamics to apitegromab efficacy in patients with later-onset spinal muscular atrophy (Types 2 and 3 SMA): Results from the TOPAZ study
    Crawford, Thomas
    Place, Amy
    Barrett, Doreen
    Cote, Shaun
    Nomikos, George
    Song, Guochen
    Bilic, Sanela
    Kalra, Ashish
    Sadanowicz, Mara
    O'Neil, Janet
    Iarrobino, Ryan
    Kertesz, Nathalie
    Chyung, Yung
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2021, 429
  • [22] Nusinersen in Infants Diagnosed with Spinal Muscular Atrophy (SMA): Study Design and Initial Interim Efficacy and Safety Findings from the Phase 3 International ENDEAR Study
    Kuntz, Nancy
    Farwell, Wildon
    John, Zhenshao
    Sun, Zhong Peng
    Gheuens, Sarah
    Schneider, Eugene
    Finkel, Richard
    NEUROLOGY, 2017, 88
  • [23] Nusinersen in Infants Who Initiate Treatment in a Presymptomatic Stage of Spinal Muscular Atrophy (SMA): Interim Efficacy and Safety Results From the Phase 2 NURTURE Study
    Crawford, T.
    De Vivo, D.
    Bertini, E.
    Hwu, W. L.
    Foster, R.
    Bhan, I
    Farwell, W.
    Reyna, S.
    ANNALS OF NEUROLOGY, 2018, 84 : S392 - S392
  • [24] Nusinersen in Infants Who Initiatte Treatment in a Presymptomatic Stage of Spinal Muscular Atrophy (SMA): Interim Efficacy and Safety Results From the Phase 2 NURTURE Study
    De Vivo, Darryl C.
    Topaloglu, Haluk
    Swoboda, Kathryn J.
    Bertini, Enrico
    Hwu, Wuh-Liang
    Crawford, Thomas O.
    Foster, Richard
    Bhan, Ishir
    Fradette, Stephanie
    Farwell, Wildon
    Reyna, Sandra P.
    NEUROLOGY, 2019, 92 (15)
  • [25] NEUROMUSCULAR DISEASE Long-term benefits of nusinersen in later-onset spinal muscular atrophy
    Fyfe, Ian
    NATURE REVIEWS NEUROLOGY, 2019, 15 (07) : 368 - 369
  • [26] Interim Report on the Safety and Efficacy of Longer-Term Treatment With Nusinersen in Infantile-Onset Spinal Muscular Atrophy (SMA): Updated Results From the SHINE Study
    Finkel, Richard S.
    Castro, Diana
    Farrar, Michelle A.
    Tulinius, Mar
    Krosschell, Kristin J.
    Saito, Kayoko
    Zhang, Yiwei
    Bhan, Ishir
    Farwell, Wildon
    Reyna, Sandra P.
    NEUROLOGY, 2019, 92 (15)
  • [27] Interim Report on the Safety and Efficacy of Longer-term Treatment with Nusinersen in Infantile-onset Spinal Muscular Atrophy (SMA): Updated Results from the SHINE Study
    Finkel, R.
    Castro, D.
    Farrar, M.
    Tulinius, M.
    Krosschell, K.
    Saito, K.
    Reyna, S.
    Zhang, Y.
    Bhan, I
    Wong, J.
    Farwell, W.
    ANNALS OF NEUROLOGY, 2019, 86 : S122 - S123
  • [28] Interim Efficacy and Safety Results from the Phase 2 NURTURE Study Evaluating Nusinersen in Presymptomatic Infants with Spinal Muscular Atrophy
    De Vivo, Darryl C.
    Hwu, Wuh-Liang
    Reyna, Sandra P.
    Farwell, Wildon
    Gheuens, Sarah
    Sun, Peng
    Zhong, Zhenshao John
    Su, John
    Schneider, Eugene
    Bertini, Enrico
    NEUROLOGY, 2017, 88
  • [29] Safety Profile of Nusinersen in Presymptomatic and Infantile-Onset Spinal Muscular Atrophy (SMA): Interim Results From the NURTURE and ENDEARSHINE Studies
    Darras, Basil T.
    De Vivo, Darryl C.
    Farrar, Michelle A.
    Mercuri, Eugenio
    Finkel, Richard S.
    Foster, Richard
    Farwell, Wildon
    Bhan, Ishir
    NEUROLOGY, 2020, 94 (15)
  • [30] Cost Effectiveness of Nusinersen in the Treatment of Patients with Infantile-Onset and Later-Onset Spinal Muscular Atrophy in Sweden
    Zuluaga-Sanchez, Santiago
    Teynor, Megan
    Knight, Christopher
    Thompson, Robin
    Lundqvist, Thomas
    Ekelund, Mats
    Forsmark, Annabelle
    Vickers, Adrian D.
    Lloyd, Andrew
    PHARMACOECONOMICS, 2019, 37 (06) : 845 - 865
12345